当前位置: 首页 >> 检索结果
共有 3506 条符合本次的查询结果, 用时 6.6265565 秒

21. Token-guided multimodal prognosis in hepatocellular carcinoma: a framework steered by tumour-stroma ratio.

作者: He-Yu Huang.;Kun Wu.;Li-Mei Qu.;Xiao-Dong Sun.;Ming-Yue Li.;Feng Wei.;Ping Zhang.;Alfred Wei Chieh Kow.;Yu-Guo Chen.;Mei-Shan Jin.;Liang Guo.;Wei Qiu.;Meng Wang.;Xiao-Ju Shi.;Jun-Feng Ye.;Chuan-Hao Hu.;Yue-Xuan Zhao.;Yu Huang.;Zhong-Qi Fan.;Yu-Shan Zheng.;Feng-Ying Xie.;Guo-Yue Lv.
来源: Gut. 2026年
The tumour-stroma ratio (TSR) is a potential prognostic indicator, yet hindered by quantification challenges and conflicting reports.

22. Optimal use of rifaximin in diverticular disease of the colon: use less for use better.

作者: Antonio Tursi.
来源: Gut. 2026年

23. When a pancreatic pseudocyst is not a pseudocyst: diagnostic pitfalls and complications.

作者: Jianing Li.;Yonghao Chen.;Xiaoyin Bai.;Yunlu Feng.
来源: Gut. 2026年

24. Steatosis severity and metabolic fingerprints after HCV eradication: toward an individualised approach to HCC surveillance after HCV cure.

作者: Lucia Parlati.;Marc Bourliere.
来源: Gut. 2026年

25. Roseburia inulinivorans increases muscle strength.

作者: Borja Martinez-Tellez.;Milena Schönke.;Artemiy Kovynev.;Esther Garcia-Dominguez.;Lourdes Ortiz-Alvarez.;Aswin Verhoeven.;Ranko Gacesa.;Arnau Vich Vila.;Quinten Raymond Ducarmon.;David Jimenez-Pavon.;Maria Del Carmen Gomez-Cabrera.;Rinse K Weersma.;Wiep-Klaas Smits.;Martin Giera.;Jonatan R Ruiz.;Patrick Cn Rensen.
来源: Gut. 2026年
Gut bacteria have been implicated in a wide range of health conditions, yet their potential role in preventing and treating muscle-wasting disorders remains largely unexplored.

26. Methodological and reporting considerations for self-reported NCGWS prevalence.

作者: Hu Fu.
来源: Gut. 2026年

27. Rifaximin in symptomatic uncomplicated diverticular disease: a stewardship perspective following the Fiesole Consensus.

作者: Wojciech Marlicz.;Marcin Krawczyk.;Piotr Milkiewicz.
来源: Gut. 2026年

28. SLC6A14-mediated carnitine transmembrane uptake from PPARγ+ cancer-associated fibroblasts promotes recurrence of pancreatic cancer.

作者: Junfeng Zhang.;Jianyou Gu.;Xianxing Wang.;Renpei Xia.;Jiali Yang.;Mei Gao.;Xiang Chen.;Yongjun Yang.;Mingda Tan.;Yangyang Shang.;Jianbo Li.;Pijiang Sun.;Lei Cai.;Jifeng Xiang.;Tao Zhang.;Kun Wu.;Ashok K Saluja.;Huaizhi Wang.;Zhe-Sheng Chen.;Shixiang Guo.
来源: Gut. 2026年
Postoperative recurrence is a major contributor to the dismal prognosis of patients with pancreatic cancer (PC). Defining the molecular features of PC with recurrence is crucial for the development of effective therapeutic strategies.

29. Post-infection disorders of the gut: of latitude and longitude.

作者: Kok Ann Gwee.
来源: Gut. 2026年

30. Appearances can be deceiving: an ulcerated oesophageal lesion.

作者: Joana Camões Neves.;Dalila Costa.;Carla Rolanda.
来源: Gut. 2026年

31. Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models.

作者: Jungen Hu.;Tianxu Liu.;Mara Klöhn.;Andrew Freistaedter.;Elif Toprak.;Huanting Chi.;André Gömer.;Lilli Pottkaemper.;Paula Jordan.;Xinyue Yang.;He Zhang.;Johanna Becker.;Shirin Nkongolo.;Volker Lohmann.;Eike Steinmann.;Lin Wang.;Viet Loan Dao Thi.
来源: Gut. 2026年
Hepatitis E virus (HEV) infections remain a global health concern. Immunocompromised patients are at an increased risk of developing chronic HEV infection and thereby severe liver disease. Current off-label regimens are suboptimal with treatment failure being reported. Therefore, there is an urgent need for an effective anti-HEV treatment.

32. Optimising mono-antibiotic eradication regimen by potent acid inhibitor and bismuth: a potential solution to rising clarithromycin resistance in Helicobacter pylori.

作者: Yu-Hwa Liu.;I-Ting Wu.;Tzung-Jiun Tsai.;Ping-I Hsu.;Deng-Chyang Wu.;John Kao.
来源: Gut. 2026年

33. Novel insights into autoimmune gastritis: clinical profile and gastric neoplastic risk from an international multicentre study.

作者: Marco Vincenzo Lenti.;Emanuela Miceli.;Irfan Soykan.;Arnoldo Riquelme.;Gonzalo Latorre.;Marcia R Cruz-Correa.;Olga L Díaz-Miranda.;Hilmaris Centeno-Girona.;Ingrid M Montes-Rodríguez.;Maria Gonzalez-Pons.;Ken Haruma.;Peter Malfertheiner.;Marino Venerito.;Julian-Yannick Baur.;Monika Laszkowska.;Vivian E Strong.;Tamara Matysiak-Budnik.;Amaury Druet.;Nicolas Chapelle.;Jerome Martin.;Shailja C Shah.;Mārcis Leja.;Sara Massironi.;Edith Lahner.;Bruno Annibale.;Alessandra Bonfichi.;Gabriele Natalello.;Carmine Frenna.;Clarissa Petrucci.;Andrea Quadrelli.;Mariangela Delliponti.;Marco Paulli.;Alessandro Vanoli.;Shamim Joudaki.;Francisca Venezian.;Juan Carlos Roa.;Sara Maquilon.;Alberto Espino.;Jose Ignacio Vargas.;Elena M De Giorgi.;Valeria Musella.;Gino Roberto Corazza.;Catherine Klersy.;M Constanza Camargo.;Antonio Di Sabatino.
来源: Gut. 2026年
International comparative data on autoimmune gastritis (AIG) remain limited.

34. Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes.

作者: Panayiotis Louca.;Sarah Manning.;Eleanor Hackney.;Linda Sharp.;Mark A Hull.;Sara Koo.;Gregory R Young.;Guy S Taylor.;Yashvee Dunneram.;Suparna Mitra.;James S Hampton.;Christina Dobson.;Laura J Neilson.;Caroline Addison.;Emad M El-Omar.; .;Christopher J Stewart.;Colin J Rees.
来源: Gut. 2026年
While colorectal cancer (CRC) has been linked to the gut microbiome, it remains unclear whether specific microbial signatures are detectable in precursor lesions such as adenomatous polyps, serrated lesions or sessile serrated lesions.

35. High versus gradually increasing energy nutrition in the early phase of acute pancreatitis (GOULASH): a multicentre double-blind randomised clinical trial.

作者: Katalin Márta.;Marie Anne Engh.;Áron Vincze.;Bálint Erőss.;Péter J Hegyi.;Alexandra Mikó.;Ferenc Izbéki.;Mária Papp.;Péter Mátrai.;Zsolt Abonyi-Tóth.;Nándor Faluhelyi.;Andrea Szentesi.;Péter Hegyi.; .
来源: Gut. 2026年75卷5期995-1002页
Acute pancreatitis (AP) is among the most common gastrointestinal diseases requiring hospitalisation, often with severe outcomes and no disease-specific therapy. Nutritional support has been proven to improve outcome, but little is known regarding optimal timing and composition.

36. Parental obesity imprints offspring risk for MASLD: act now to protect future generations.

作者: Youngmi Jung.;Paul Horn.
来源: Gut. 2026年

37. Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD.

作者: Wenhui Wu.;Qiang Gao.;Suping Hai.;Xitang Li.;Binghui Yu.;Junjian Hu.;Feiyang Xu.;Xizhe Zheng.;Yuanyuan Wang.;Awang Danzeng.;Bin-Hao Zhang.;Qin Ning.;Xiaojing Wang.
来源: Gut. 2026年
Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic hepatitis B (CHB), yet its impact on liver-related outcomes remains controversial. Although the stimulator of interferon genes (STING) pathway is pivotal in innate immunity, its involvement in CHB-MASLD comorbidity is undefined.

38. Are the drugs already on the shelf? Repurposing therapy for pancreatitis.

作者: Christopher E Forsmark.
来源: Gut. 2026年

39. Screening for preclinical Crohn's disease based on capsule endoscopy is not yet ready.

作者: Brecht Hens.;Geert D'Haens.;Ryan C Ungaro.;Jean-Frederic Colombel.
来源: Gut. 2026年

40. Absolute risk stratification of HCC after HCV cure in MASLD: do advanced steatosis and dysglycaemia add beyond liver stiffness?

作者: Dandan Weng.;Jiale Chen.;Changhui Lin.
来源: Gut. 2026年
共有 3506 条符合本次的查询结果, 用时 6.6265565 秒